Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: zolimomab aritox, elx-02, citatuzumab bogatox +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 156 | 0.82 |
| pathways Reactome | 16 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12598
Sealed predictions
- RPL13 in dopamine neurons, braak+0.43 (p 0.244) → +0.27 (p 0.487)receipt 12605
Swarm cases
receipt 12605: RPL13 in dopamine neurons, braak
- power
- full sample +0.37 (p 0.130, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.33 (p 0.176, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.130, n 18). could be the mix.
- skeptic
- leave-one-out range +0.29 to +0.51, sign flips 0; without severely affected donors +0.37 (p 0.130, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPL13 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts